CD38-Induced Metabolic Dysfunction Primes Multiple Myeloma Cells for NAD⁺-Lowering Agents

Area of Science:

• Biochemistry
• Cancer Biology
• Immunology

Background:

• Cancer cells increase NAD+ biosynthesis for energy and growth, presenting a metabolic vulnerability.
• CD38, a NAD+-degrading enzyme, is a validated target in multiple myeloma (MM) therapy, with anti-CD38 antibodies forming a treatment backbone.

Purpose of the Study:

• To investigate the mechanisms by which CD38 promotes tumorigenesis and its metabolic effects.
• To explore how targeting CD38 can be leveraged to enhance anti-cancer strategies, particularly in multiple myeloma.

Main Methods:

• Investigated the effects of CD38 upregulation on intracellular NAD+ levels and mitochondrial function.
• Utilized genetic and pharmacologic approaches to modify CD38 surface levels and assess impact on MM cells.
• Analyzed alterations in mitochondrial dynamics and cellular energetic remodeling.

Main Results:

• CD38 upregulation leads to significant intracellular NAD+ depletion.
• This depletion impairs mitochondrial fitness and increases oxidative stress in cancer cells.
• Targeting CD38 primes multiple myeloma cells for NAD+-lowering agents by altering mitochondrial dynamics and energetic remodeling.

Conclusions:

• CD38 manipulation is a novel strategy to enhance the efficacy of NAD+-lowering agents.
• The findings provide a rationale for clinical studies combining CD38 targeting with NAD+-lowering therapies in multiple myeloma patients.